These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 7526527)

  • 21. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
    Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
    Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy.
    Corn BW; Hanks GE; Lee WR; Bonin SR; Hudes G; Schultheiss T
    J Urol; 1995 Jun; 153(6):1855-9. PubMed ID: 7538598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA level, and DNA ploidy status.
    Ross JS; Nazeer T; Figge HL; Fisher HA; Rifkin MD
    Am J Clin Pathol; 1995 Jul; 104(1):36-41. PubMed ID: 7541934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
    Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
    Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.
    Zagars GK; von Eschenbach AC
    Cancer; 1993 Jul; 72(2):538-48. PubMed ID: 7686443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In treating localized prostate cancer the efficacy of cryoablation is independent of DNA ploidy type.
    Bahn DK; Silverman P; Lee F; Badalament R; Bahn ED; Rewcastle JC
    Technol Cancer Res Treat; 2004 Jun; 3(3):253-7. PubMed ID: 15161318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.
    Pollack A; Grignon DJ; Heydon KH; Hammond EH; Lawton CA; Mesic JB; Fu KK; Porter AT; Abrams RA; Shipley WU
    J Clin Oncol; 2003 Apr; 21(7):1238-48. PubMed ID: 12663710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic parameters and flow cytometric ploidy analysis in predicting recurrence in carcinoma of the prostate.
    Voges GE; Eigner EB; Ross W; Sussman H; Stöckle M; Freiha FS; Stamey TA
    Eur Urol; 1993; 24(1):132-9. PubMed ID: 8365433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group.
    Lattanzi JP; Hanlon AL; Hanks GE
    Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):569-73. PubMed ID: 9231681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
    Lankford SP; Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):327-33. PubMed ID: 9226319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
    Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer.
    Zagars GK; Pollack A
    Cancer; 1993 Aug; 72(3):832-42. PubMed ID: 7687516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer.
    Ritter MA; Gilchrist KW; Voytovich M; Chappell RJ; Verhoven BM
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):574-80. PubMed ID: 12062599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation.
    Diaz JI; Mora LB; Austin PF; Muro-Cacho CA; Cantor AB; Nicosia SV; Pow-Sang JM
    Urology; 1999 May; 53(5):931-8. PubMed ID: 10223486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flow cytometric DNA analysis of fresh prostatic resections. Correlation with conventional prognostic parameters in patients with prostate cancer.
    Hussain MH; Powell I; Zaki N; Maciorowski Z; Sakr W; KuKuruga M; Visscher D; Haas GP; Pontes JE; Ensley JF
    Cancer; 1993 Nov; 72(10):3012-9. PubMed ID: 7693326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative analysis of prognostic factors in men undergoing radical prostatectomy for adenocarcinoma of the prostate, including DNA ploidy, surgical tumor stage, prostatic specific antigen, Gleason grade, and age.
    Shockley KF; Maatman TJ; Carothers GC; Warzynski MJ
    Prostate; 1996 Jul; 29(1):46-50. PubMed ID: 8685055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors.
    Zincke H; Bergstralh EJ; Larson-Keller JJ; Farrow GM; Myers RP; Lieber MM; Barrett DM; Rife CC; Gonchoroff NJ
    Cancer; 1992 Jul; 70(1 Suppl):311-23. PubMed ID: 1600493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.